Affiliation:
1. Yevdokimov Moscow State University of Medicine and Dentistry
2. Ilyinsky Hospital
Abstract
Gastroesophageal reflux disease (GERD) is one of the most widespread gastrointestinal pathologies and the most common reason for seeking medical care at the level of a primary link of public health services in many countries around the world. The classic clinical presentations of GERD are heartburn, belching, and regurgitation (spitting up), but the overall spectrum of GERD symptoms is broader and more heterogeneous in scope, including extraesophageal symptoms. Clinical and/or endoscopic refractoriness of some patients to the standard proton pump inhibitors (PPIs) therapy remains a global challenge in the management of patients with GERD at the current stage of clinical medicine development. A medicinal product of a fundamentally new class was developed to optimize the treatment of patients with GERD – an esophageal mucosal protectant, which consists of a fixed combination of hyaluronic acid and chondroitin sulfate dissolved in a bioadhesive carrier (polymerase 407). This review is primarily aimed at systematizing data on the efficacy of the esophageal mucosal protectant in the treatment of patients with GERD. The systematic review that summarized the results of 10 studies involving 1090 patients with GERD showed that adding this esophageal mucosal protectant to the PPI therapy increased the efficacy of GERD therapy, as well as improved the frequency of symptomatic, endoscopic and morphological response to the treatment. Such combination therapy contributes to the optimization of the treatment of patients with various disease phenotypes, regress of both esophageal and extraesophageal symptoms, and potentiation of repair of the esophageal mucosa. To increase the efficacy of treatment and improve the prognosis of the disease, this approach should be implemented at the early stages of therapy in real clinical practice.
Reference33 articles.
1. Maev I.V., Busarova G.A., Andreev D.N. Bolezni pishchevoda. M.: GEOTARMedia; 2019. 33 s. Rezhim dostupa: https://medknigaservis.ru/wp-content/uploads/2019/01/NF0012672.pdf. Maev I.V., Busarova G.A., Andreev D.N. Diseases of the Esophagus. Moscow: GEOTAR-Media; 2019. 33 p. (In Russ.) Available at: https://medknigaservis.ru/wp-content/uploads/2019/01/NF0012672.pdf.
2. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zairat'yants O.V. i dr. Rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniyu gastroezofageal'noi reflyuksnoi bolezni. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2020;30(4):70–97. https://doi.org/10.22416/1382-4376-2020-30-4-70-97. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-70-97.
3. Katz P.O., Dunbar K.B., Schnoll-Sussman F.H., Greer K.B., Yadlapati R., Spechler S.J. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27–56. https://doi.org/10.14309/ajg.0000000000001538.
4. GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):561–581. Available at: https://pubmed.ncbi.nlm.nih.gov/32246941/.
5. Nirwan J.S., Hasan S.S., Babar Z.U., Conway B.R., Ghori M.U. Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis. Sci Rep. 2020;10(1):5814. https://doi.org/10.1038/s41598-020-62795-1.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献